Modulation of circulating osteocalcin-expressing monocytes by glucagon like peptide-1 receptor agonists in type 2 diabetes: an exploratory pilot study
Acta Diabetologica · 21.09.2026 · 63 (12) · 2189-2196
DOI: 10.1007/s00592-026-02778-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift Acta Diabetologica, online erschienen am 21.09.2026. Verfasst von Andrea Carafa und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Experimental Medicine, Sapienza University of Rome, Viale Regina Elena 324, 00161, Rome, Italy. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Monocytes, Osteocalcin, Hypoglycemic Agents. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Università degli Studi di Roma La Sapienza.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Context
The phenotypic drift of circulating monocytes toward osteoblast-like cells expressing osteocalcin (OCN) has been linked to vascular calcification in individuals with type 2 diabetes (T2D). The synergistic action of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and metformin may reduce the cardiovascular risk by modulating OCN-expressing monocytes, representing a novel mechanism of cardiovascular protection.
Objective
To investigate the impact of GLP-1 RA add-on metformin therapy on the percentage of circulating CD14 + OCN + monocytes. Research design and methods This longitudinal study enrolled patients with T2D receiving metformin monotherapy who either initiated GLP-1 RA therapy (Group A, n = 7) or did not (Group B, n = 28). Clinical parameters and circulating CD14+OCN+ cell levels were assessed at baseline (V0), after 1 week (V1) and after 12 weeks (V2). In vitro experiments were conducted using peripheral blood mononuclear cells (PBMCs) from healthy volunteers (n = 10), treated with metformin or exendin-4 for 24 h.
Results
In group A, the percentage of CD14+OCN+ significantly decreased from baseline (4.5 [2.5–7.6]) to V2 (2.2 [1.73–4.9]% p = 0.019). This reduction was already significant at V1 (p = 0.039). No significant change over time was observed in Group B (p = 0.31). In vitro treatment of PBMCs with metformin significantly reduced the percentage of CD14 + OCN + cell (− 34.9%, p < 0.0001), whereas exendin-4 yielded a non-significant downward trend (− 8.5%, p = 0.1).
Conclusion
GLP-1 RA add-on therapy to metformin reduces OCN expression in circulating monocytes in patients with T2D. In vitro data suggest that this effect might not result from a direct effect on mononuclear cells, but rather from indirect systemic mechanisms that warrant further investigation. These findings identify OCN-expressing monocytes as a potential novel therapeutic target for GLP-1 RA to reduce cardiovascular risk in T2D.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Experimental Medicine, Sapienza University of Rome, Viale Regina Elena 324, 00161, Rome, Italy.
- Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy.
- Diabetes Unit, Department of Internal Medicine, Endocrinology and Metabolism and Infectious Disease, Policlinico Umberto I University Hospital, Rome, Italy.
- Unit of Cardiology, Department of Medicine, Fondazione Policlinico Universitario Campus Bio-Medico, Rome, Italy.
- Department of Experimental Medicine, Sapienza University of Rome, Viale Regina Elena 324, 00161, Rome, Italy. ernesto.maddaloni@uniroma1.it.
- Diabetes Unit, Department of Internal Medicine, Endocrinology and Metabolism and Infectious Disease, Policlinico Umberto I University Hospital, Rome, Italy. ernesto.maddaloni@uniroma1.it.
Förderung
- Università degli Studi di Roma La Sapienza
Zitieren
APA
Carafa, A., Sessa, R. L., Amendolara, R., Zampetti, S., Mignogna, C., Sciarra, F., D'Onofrio, L., Risi, R., Venneri, M. A., Cavallari, I., Maddaloni, E., & Buzzetti, R. (2026). Modulation of circulating osteocalcin-expressing monocytes by glucagon like peptide-1 receptor agonists in type 2 diabetes: an exploratory pilot study. Acta Diabetologica, 63(12), 2189-2196. https://doi.org/10.1007/s00592-026-02778-2
Vancouver
Carafa A, Sessa RL, Amendolara R, Zampetti S, Mignogna C, Sciarra F, et al. Modulation of circulating osteocalcin-expressing monocytes by glucagon like peptide-1 receptor agonists in type 2 diabetes: an exploratory pilot study. Acta Diabetologica. 2026;63(12):2189-2196. doi:10.1007/s00592-026-02778-2
BibTeX
@article{Carafa2026,
author = {Carafa, Andrea and Sessa, Rosario Luigi and Amendolara, Rocco and Zampetti, Simona and Mignogna, Carmen and Sciarra, Francesca and D'Onofrio, Luca and Risi, Renata and Venneri, Mary Anna and Cavallari, Ilaria and Maddaloni, Ernesto and Buzzetti, Raffaella},
title = {Modulation of circulating osteocalcin-expressing monocytes by glucagon like peptide-1 receptor agonists in type 2 diabetes: an exploratory pilot study},
journal = {Acta Diabetologica},
year = {2026},
volume = {63},
number = {12},
pages = {2189--2196},
doi = {10.1007/s00592-026-02778-2}
}
EUVIMED